Recent advances in salmonellosis treatment based on in vitro susceptibilities.
Chloramphenicol-resistant strains of Salmonella typhi (MIC 60 micrograms/ml), chloramphenicol and ampicillin-resistant strains of Salmonella typhimurium as well as multiresistant strains of various salmonella serotypes were found to be very sensitive to cephradine (MIC 0.078-0.625 micrograms/ml). Ten patients with Salmonella typhi bacteremia were successfully treated with cephradine; all the patients' strains were chloramphenicol-resistant. Cephradine appears to warrant further clinical trial for the treatment of salmonellosis.
D000668:Ampicillin Resistance; D002515:Cephradine / Q000494:pharmacology / Q000627:therapeutic use*; D002702:Chloramphenicol Resistance; D006801:Humans; D008826:Microbial Sensitivity Tests; D012475:Salmonella / Q000187:drug effects; D012480:Salmonella Infections / Q000188:drug therapy* / Q000382:microbiology
D002515:Cephradine